Original ResearchThe role of S100a4 (Mts1) in Apc- and Smad4-driven tumour onset and progression

- Genetic ablation or overexpression of S100a4 in both Apc- and Smad4-mutant mice do not affect intestinal tumour initiation.
- S100a4 overexpression in Apc1638N/+/KRASV12G mice increases the dissemination of intestinal tumour cells to the liver.
- S100a4 deficiency results in a reduction of desmoids suggesting a novel role for S100a4 in desmoid formation.
- S100a4 is co-expressed together with mesenchymal stem cell (MSC) markers in desmoid tumours.

IntroductionS100a4 is a calcium-binding protein belonging to the family of S100-proteins, highly expressed in different stromal cell types. S100A4 has been reported as a prognostic marker in colorectal cancer in association with tumour progression and metastasis.MethodsIn this study, we analysed the in vivo role of S100a4 in intestinal tumour initiation and progression using different transgenic and knockout mouse models.ResultsWe found that genetic ablation or overexpression of S100a4 in both Apc- and Smad4-mutant mice do not affect tumour initiation in the intestinal tract. In contrast, S100a4 epithelial overexpression in Apc1638N/+/KRASV12G mice increases the dissemination of intestinal tumour cells to the liver, in agreement with its role in tumour metastasis. Moreover, we report a novel role for S100a4 in desmoid formation where S100a4 deficiency results in a significant reduction of the tumour burden characteristic of the Apc1638N model. In agreement with these results, S100a4 appears to be co-expressed together with mesenchymal stem cell (MSC) markers in desmoid tumours from Apc1638N/+ mice, as well as from sporadic and hereditary human desmoids.ConclusionOur data provide the first report on the in vivo role of S100a4 in intestinal tumourigenesis and describe a new role for S100a4 in the aetiology of desmoids formation.